GSK Signs Record Israeli Settlement Of Avandia Diabetes Drug Suit
This article was originally published in PharmAsia News
An Israeli class-action suit against GlaxoSmithKline over its Avandia (rosiglitazone) diabetes drug has reached a record compromise settlement by a drug maker in Israel.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.